Vikram Verghese Sells 4,593 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 4,593 shares of Heartflow stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $50.24, for a total value of $230,752.32. Following the sale, the chief financial officer owned 180,196 shares in the company, valued at $9,053,047.04. This trade represents a 2.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Tuesday, September 15th, Vikram Verghese sold 668 shares of Heartflow stock. The shares were sold at an average price of $50.01, for a total value of $33,406.68.
• On Friday, September 11th, Vikram Verghese sold 29,714 shares of Heartflow stock. The stock was sold at an average price of $50.06, for a total value of $1,487,482.84.
• On Tuesday, September 8th, Vikram Verghese sold 6,640 shares of Heartflow stock. The stock was sold at an average price of $50.03, for a total value of $332,199.20.
• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The shares were sold at an average price of $49.69, for a total value of $1,368,462.60.
• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The stock was sold at an average price of $50.60, for a total transaction of $297,325.60.

Heartflow Price Performance

Shares of Heartflow stock opened at $48.30 on Thursday. The firm’s fifty day simple moving average is $36.83 and its 200-day simple moving average is $31.38. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $51.78. The stock has a market capitalization of $4.20 billion and a price-to-earnings ratio of -26.39.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company had revenue of $64.08 million for the quarter. Heartflow’s quarterly revenue was up 47.7% on a year-over-year basis. Analysts anticipate that Heartflow, Inc. will post -0.75 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. XXEC Inc. acquired a new stake in Heartflow in the second quarter valued at $2,524,764,000. BlackRock Inc. acquired a new position in shares of Heartflow during the 2nd quarter worth $152,502,000. Bamco Inc. NY purchased a new position in shares of Heartflow in the 2nd quarter valued at about $94,625,000. Jupiter Topco LLC acquired a new stake in shares of Heartflow in the second quarter valued at about $70,983,000. Finally, Janus Henderson Group PLC grew its position in Heartflow by 152.0% during the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after buying an additional 1,315,416 shares during the period.

Key Headlines Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow’s latest quarterly results remain a fundamental positive: revenue increased 47.7% year over year to $64.08 million, while the $0.07-per-share loss was substantially better than the $0.22 loss analysts expected. Heartflow earnings information
• Positive Sentiment: Analyst sentiment is still broadly favorable, with a consensus “Moderate Buy” rating. UBS initiated coverage with a $55 price target, although the broader average target of $44.88 is below recent trading levels.
• Neutral Sentiment: Institutional interest has provided some support, including Squarepoint Ops increasing its position by 72% and several funds initiating new stakes during the second quarter.
• Negative Sentiment: CFO Vikram Verghese sold 34,975 shares for approximately $1.75 million between September 11 and September 15 at prices near $50. He still directly owns 179,528 shares, but the repeated sales reduce insider ownership and may concern momentum-focused investors. The transactions were conducted under a pre-arranged trading plan. CFO SEC filing
• Negative Sentiment: CEO John C.M. Farquhar sold 38,900 shares for roughly $1.82 million in transactions dated September 10–11. The sales occurred as Heartflow traded near its 52-week high, reinforcing concerns that executives are taking profits and likely contributing to the stock’s recent decline. Heartflow CEO share sale
• Negative Sentiment: Heartflow remains unprofitable, with a negative net margin and analysts expecting a full-year loss of approximately $0.75 per share. Its valuation and sharp rise above the 50-day and 200-day moving averages could increase sensitivity to profit-taking.

Wall Street Analysts Forecast Growth

Several research firms have commented on HTFL. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (up from $38.00) on shares of Heartflow in a research note on Friday, August 14th. Wells Fargo & Company boosted their target price on Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Robert W. Baird set a $45.00 price objective on shares of Heartflow in a research report on Friday, August 14th. Finally, Stifel Nicolaus lifted their target price on shares of Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.88.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).